Literature DB >> 19183876

Anti-androgen-independent prostate cancer effects of ginsenoside metabolites in vitro: mechanism and possible structure-activity relationship investigation.

Wei Li1, Yong Liu, Jiang-Wei Zhang, Chun-Zhi Ai, Nan Xiang, Hui-Xin Liu, Ling Yang.   

Abstract

Treatment of androgen-independent prostate cancer (AIPC) remains unsatisfactory. In our present experiment, natural occurring ginsenosides (NOGs) and intestinal bacterial metabolites (IBMs) were employed to investigate their anti-AIPC cell growth activity using PC-3 cells. Our results showed that the IBMs exerted more portent anti-AIPC activity than NOGs, by decreasing survival rate, inhibiting proliferation, inducing apoptosis, and leading to cell cycle arrest in AIPC PC-3 cells. The increase of LogP and decrease of C-6 steric hindrance, which were caused by deglycosylation by intestinal bacteria, may be the reason for the higher anti-AIPC activity of IBMs.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19183876     DOI： 10.1007/s12272-009-1117-1

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN： 0253-6269            Impact factor:   4.946


  13 in total

1.  Rapamycin inhibits acrolein-induced apoptosis by alleviating ROS-driven mitochondrial dysfunction in male germ cells.

Authors:  X He; W Song; C Liu; S Chen; J Hua
Journal:  Cell Prolif       Date:  2014-01-31       Impact factor: 6.831

Review 2.  Pharmacokinetic Drug Interactions with Panax ginseng.

Authors:  Meenakshi R Ramanathan; Scott R Penzak
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-08       Impact factor: 2.441

Review 3.  Ginsenosides from American ginseng: chemical and pharmacological diversity.

Authors:  Lian-Wen Qi; Chong-Zhi Wang; Chun-Su Yuan
Journal:  Phytochemistry       Date:  2011-03-09       Impact factor: 4.072

4.  Inhibition of P-glycoprotein leads to improved oral bioavailability of compound K, an anticancer metabolite of red ginseng extract produced by gut microflora.

Authors:  Zhen Yang; Jing-Rong Wang; Tao Niu; Song Gao; Taijun Yin; Ming You; Zhi-Hong Jiang; Ming Hu
Journal:  Drug Metab Dispos       Date:  2012-05-14       Impact factor: 3.922

5.  A novel drug-phospholipid complex enriched with micelles: preparation and evaluation in vitro and in vivo.

Authors:  Hai-jian Xia; Zhen-hai Zhang; Xin Jin; Qin Hu; Xiao-yun Chen; Xiao-bin Jia
Journal:  Int J Nanomedicine       Date:  2013-02-04

6.  Ginsenosides as Anticancer Agents: In vitro and in vivo Activities, Structure-Activity Relationships, and Molecular Mechanisms of Action.

Authors:  Subhasree Ashok Nag; Jiang-Jiang Qin; Wei Wang; Ming-Hai Wang; Hui Wang; Ruiwen Zhang
Journal:  Front Pharmacol       Date:  2012-02-28       Impact factor: 5.810

7.  Rapid preparation of rare ginsenosides by acid transformation and their structure-activity relationships against cancer cells.

Authors:  Kai Quan; Qun Liu; Jin-Yi Wan; Yi-Jing Zhao; Ru-Zhou Guo; Raphael N Alolga; Ping Li; Lian-Wen Qi
Journal:  Sci Rep       Date:  2015-02-26       Impact factor: 4.379

8.  Inhibitory Effects of Ginsenoside Ro on the Growth of B16F10 Melanoma via Its Metabolites.

Authors:  Si-Wen Zheng; Sheng-Yuan Xiao; Jia Wang; Wei Hou; Ying-Ping Wang
Journal:  Molecules       Date:  2019-08-17       Impact factor: 4.411

Review 9.  Metabolic and functional diversity of saponins, biosynthetic intermediates and semi-synthetic derivatives.

Authors:  Tessa Moses; Kalliope K Papadopoulou; Anne Osbourn
Journal:  Crit Rev Biochem Mol Biol       Date:  2014-10-06       Impact factor: 8.250

Review 10.  Anticancer Activities of Protopanaxadiol- and Protopanaxatriol-Type Ginsenosides and Their Metabolites.

Authors:  Xiao-Jia Chen; Xiao-Jing Zhang; Yan-Mei Shui; Jian-Bo Wan; Jian-Li Gao
Journal:  Evid Based Complement Alternat Med       Date:  2016-06-30       Impact factor: 2.629
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.